Thl/Th2 CYTOKINE BALANCE IN ARTHRITIS
PIERRE MIOSSEC and WIM v a n d e n BERG Studies of the contribution of cytokines to the pathogenesis of rheumatoid arthritis (RA) have focused largely on monocyte-derived proinflammatory cytokines (1) . Interleukin-1 (IL-1) and tumor necrosis factor a (TNFa), characterized as the most important ones, have been selected as significant therapeutic targets (2). The contribution of T cells to RA has been more a matter of debate and has been addressed in a number of reviews published in Arthritis & Rheumatism (3) (4) (5) . A major issue has been-and remains-the remarkable contrast be tween the presence of a T cell infiltrate and the relative failure to detect definite markers of activity of these cells. Indeed, the low level of expression and production by the rheumatoid synovium of T cell-derived cyto kines, as first described for IL-2 and interferon-y (IFNy), then extended to TNF/3 and IL-4, were a primary reason to question the direct contribution of T cells to this disease (6) .
The field has advanced recently by the descrip tion of new T cell-derived cytokines, which were as signed to various subsets of T cells. These subsets have, in turn, been associated with the development of differ ent patterns of disease in mice and humans. Finally, modulation of the cytokine profile is now considered a therapeutic mean (7) . In diseases such as RA, where a specific causative agent and/or antigen has not been identified, bypassing the antigen and acting on cytokine balance might autoimmunity and chronic inflammation (8, 9) . a way to control
Thl/Th2 cytokine balance from mice to humans
In 1986, Mosmann and Coffman showed that mouse CD4+ T cell clones could be classified into distinct subsets according to their cytokine production pattern (10) . Those studies established that IL-2 and IFNy were produced by Thl clones, whereas IL-4 and IL-5 were mostly produced by Th2 clones. Later, new cytokines were identified and were classified as T hl for TNF/3 and as Th2 for IL-6, IL-10, and IL-13. Simulta neously, a precursor (ThO) subset that produced IL-4, IL-2, and IFNy was described (11) . These precursor cells are themselves derived from virgin T cells (Thp), which secrete IL-2 following activation.
According to this simple dichotomy, Thl cyto kines favor T cell-mediated cellular immunity and cy totoxicity, delayed-type hypersensitivity (DTH), and they activate monocytes, which leads to the production of proinflammatory cytokines. Th2 cytokines favor B cell mediated-humoral immunity, induce with IL-4 and IL-13, activate eosinophils with IL-5, and deactivate monocytes, which leads to an antiinflamma tory cytokine pattern ( Figure 1 ).
Next, it was important to demonstrate that these patterns could also be recognized at a polyclonal level when looking at their tissue expression and production. Indeed, observations in animal contribution of Thl cells to DTH and the contribution of Th2 cells to allergies and some parasitic infections. It was clear from the beginning that in the mouse models, the H2 genetic background had a major role in determinmg
rnd its associ ar par The same dichotomy was later applied to human T cells, starting with T cell clones and application to various diseases (12, 13) . clones from RA synovium were found to pr amounts of IFNy, but not IL-4, which classification as Thl cells (14, 15) . A similar was reached with CD4+ T cells diabetes, thyroid by , T cell Figure 1 . The Thl/Th2 cytokine balance and biologic functions. A predominant T hl profile is implicated in T cell-mediated immunity, whereas a predominant Th2 profile is implicated in B cell-mediated immunity. The opposite effects on monocyte activation are the basis for the control of chronic inflammation. IL = interleukin; IFNy = interferon-y. than T cells, represent a major source of IL-10 (19). The same conclusion was reached for IL-6, TNFa, and granulocyte-macrophage colony-stimulating factor (GM-CSF). Thus, with regard to the relative amount of cytokine, IL-10 cannot be considered a major T cellderived cytokine.
Recently, a Th3 subset has been defined for cells producing transforming growth factor /3 (TGF/3), which is largely a monocyte/mesenchymal cell-derived growth factor. Indeed, a monocyte cytokine balance parallels the T cell cytokine balance. Monocytes are the major source of IL-12, which acts on T cells and natural killer cells to induce the production of IFNy. This leads to a strong Thl pattern. Conversely, IL-10 produced by monocytes inhibits the production of IFNy, and thus counteracts the effect of IL-12 (7) ( Figure 3 ).
Cytokine specificity inside the balance. Cytokines such as IL-4 and IL-10 have been classified as Th2 cytokines. Although they share major functions, such as the inhibition of proinflammatory cytokine production by monocytes, they have opposite effects on many other targets. For instance, IL-10 appears to be a major factor for inducing complete plasma cell differentiation when B cells are in contact with synoviocytes, an effect which is inhibited by IL-4 (20) . Similarly, differences have been sclerosis. These diseases were then classified as Thl conditions (Figure 2) . Conversely, with respect to allergies, CD4+ T cells infiltrating the conjunctiva of patients with vernal conjunctivitis or allergen-specific T cell clones obtained from patients with atopy were essentially of the Th2 type (16) . The contribution of IL-4 to scleroderma and of IL-10 to lupus led to the classification of these diseases as Th2 conditions (17) .
Extension of the Thl/Th2 cytokine balance
Production by other cell subsets. Further studies in mice and in humans showed that T cell clones could in fact produce a mixture of cytokines. In the case of arthritis, a large proportion of the heat-shock proteinspecific a//3 CD4+ clones, which produce large amounts of IFNy, also released significant amounts of IL-10 (15). revealed when comparing the responses of monocytes from blood or synovium with these cytokines (21) . IL-4 and IL-13 share most of their activities, particularly their antiinflammatory properties (22). However, the effect of IL-4 on T cells appears more potent than that of IL-13. Furthermore, the 2 cytokines use the same multichain receptor, but in a competitive manner, as shown particularly with activated synovio cytes (23) . The reason for the presence of the 2 mole cules is unclear, and the use of one or thé other cytokine for treatment would be difficult to justify.
Moreover, some of these cytokines were produced by cells other than Th cells, such as CD8+ cytotoxic T cells, y/8 T cells, and even cells other than T cells (18). IL-4 is also produced by mast cells, basophils, and eosinophils. Human IL-10 is produced by monocytes and B cells, as well as by Thl cells. In RA synovium, monocytes, rather
New members of the Thl/Th2 cytokine balance. New cytokines have been isolated, and their classifica tion is still pending. Among them, IL-17 is of particular interest in inflammation. This cytokine, which is pro duced by CD4+ T cells, acts on mesenchymal cells, such as synoviocytes, to induce the production of a proinflam matory pattern (24) , with the induction of IL-6, GM-CSF, and prostaglandin E2 production (25) . results indicate that this can be extended to other factors, such as leukemia inhibitory factor (LIF). These characteristics indicate that IL-17 can be classified as a Moreover on synoviocytes represents a new way for T cells to i mation, in particular, in association with low monocyte-derived cytokines.
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The Thl/Th2 cytokine balance in action
The dynamic pattern of the Thl/Th2 cytokine balance. The pattern of regulatory cytokine production is controlled by many parameters: the antigen structure (arthritogenic versus tolerogenic epitopes), the mode of administration versus oral), the presenting cells (dendritic cells versus B cells), and the cytokine and steroid environment (Thl versus Th2) (26) . This ability to switch between patterns may be useful se concepts to treatment. First, each Th cytokine subset induces its own production and favors the differentiation of naive T cells into the same subset. Thus IFNy induces its own produc tion and Thl cell activation, whereas IL-4 activates Th2.
The second important feature of Thl and Th2 cells is the ability of one subset to regulate the activities of the other. Both IL-4 and IL-10 are strong inhibitors of IFNy production, and IFNy inhibits IL-10 production (27) ( Figure 1 ). Early results showed the direct contri bution of the antigen. T cells from a given normal individual produce Thl cytokines in response to myco bacterial antigens and Th2 cytokines in response to allergens (13) . Furthermore, culture of normal T cells in the presence of either IFNy or IL-4 results in the development of clones of either Thl or Th2 respectively (28) .
Recent results have shown that the balance can be manipulated with mitogens level of a specific antigen. This is a critical issue when considering the treatment of diseases of unknown spe cific origin, such as RA. These studies have indies ways to induce a switch between the 2 Human umbilical cord blood naive T cells activated mitogens can be directed toward Thl when cultured in the presence of IL-12 and anti-IL-4, and toward Th2 when cultured in the presence of IL-4 and anti-IL-12 (29) . IL-12 and that of IL-4 in the switch to Thl and Th2, respectively ( Figure 3 ). critical role of ays activated by have focused on the role of the Stat transcription factors. IL-12 acts through the activation of Stat-4. Indeed, the inactivation of the Stat-4 gene in mice leads to a defect in IL-12 production, and thus of Thl functions, com bined with an increase in Th2 functions (30) . Conversely, Stat-6 is critical for IL-4-and Th2-mediated events, as shown with Stat-6 knockout mice (31, 32) .
To monitor these changes, various surface mark ers, such as CD27 and CD30, have been proposed to specifically identify these populations. However, addi tional studies have put to question their value for differentiating these subsets. Regarding arthritis, blood CD4,CD45RBdim,CD27 -T cells have been character ized as the IL-4-producing subset (33) . Their presence in the joint may represent an attempt to control inflam mation (34) . Recent studies have indicated a good correlation between the Thl pattern and the expression of the 02 chain of the IL-12 receptor (29) . Indeed IL-12 is critical for differentiation into a Thl phenotype. Similarly, the transcription factor GATA-3 has been shown to be necessary and sufficient for Th2 pattern expression in mouse T cells (35) . Additional studies are needed to determine whether these markers will be useful in the context of arthritis.
Molecules controlling the Thl/Th2 cytokine bal ance. Various molecules contribute to the control of Thl/Th2 development. The costimulatory molecules B7-1 (CD80) and B7-2 (CD86) expressed on antigenpresenting cells act as a second signal and control the differentiation of the 2 major subsets (36) . Their ligands on T cells are CD28 and CTLA-4 (37) . This second step of activation follows the first signal given by the inter action between the T cell receptor and the antigen major histocompatibility complex, which confers T cell speci ficity. CD28 costimulation was found to promote the production of Th2 cytokines by mouse T cells through an IL-4-dependent mechanism (38) .
Initial results in the mouse have indicated that activation of the B7-1 pathway stimulates the Thl sub set, whereas B7-2 activation stimulates the Th2 subset. Conversely, blockade of B7-1 was able to control Thlmediated diseases such as diabetes and encephalomyeli tis (39, 40) . However, results in other systems indicate that this represents an oversimplification (41).
Application to humans has proven to be more difficult. However, the contribution of IL-4 appears to be critical. B7-2 stimulation specifically controls IL-4 production by naive T cells, whereas both B7-1 and B7-2 can induce IL-4 production by memory T cells (42) . In the absence of the regulatory properties of IL-4, T cells remain sensitive to other regulatory cytokines, such as IL-12, which induces a strong Thl profile by inducing IFNy production. In conclusion, the presence or absence of IL-4 appears to represent the critical control for the Thl/Th2 switch.
Thl/Th2 cytokine balance in arthritis
Expression in the synovium. This simple classifi cation has been more difficult to reconstitute when looking at the cytokines produced by the synovium itself. Findings concerning the levels of these T cell-derived cytokines in RA have been contradictory and their specific detection difficult, despite infiltration of the synovium by many T cells (6, 43) . Although contradictory results have been published, the expression of IL-2 and IFNy messenger RNA (mRNA) by RA synovium was not detected in one study even with the use of the most recent and sensitive methods (44). IL-4 protein and mRNA could not be detected in synovial fluid, synovial supernatants, or the synovium itself (45) .
Cytokines such as IFNy and IL-10 could not be easily detected in the supernatants of synovium pieces and (19) . However, staining for IL-10 was endogenous IL-10 was shown to be active, since an increased production of proinflammatory cytokines was observed in the presence of an inhibitory anti-IL-10 antibody (46). As indicated above, isolated synovial T cells do produce significant levels of IFNy. Such produc tion may be sufficient to induce potent local effects (Figure 4) . The inhibitory effect of these 2 cytokines on each other may explain the absence of secretion when the secreting cells are in close contact (27) , but the inhibitory component remains insufficient to control disease activity. Similar conclusions apply to TGF/3, which are also largely present in an active form in RA (45) .
Thl/Th2 cytokine balance and the search for the cause ofRA. A large body of work has tried to isolate the specific antigen(s) that contributes to RA. The lack of an identified causative agent in autoimmune diseases re mains the major limitation to early diagnosis and treat ment. In Lyme arthritis, the bacterial antigen is well known, and the histologic appearance of the synovium is very similar to that seen in RA. T cell clones specific for the bacterial were shown to amounts of IFNy with no IL-4, as in RA (47) . Similarly, have in md leprosy (48, 49) , Along the same line, T cells infected by retrovirus human T opic virus I (HTLV-I) tend to produce an extended cytokine profile, combining T cell-derived cytokines of the type 1 pattern and monocyte-type cytokines. Such a profile could con tribute to the rheumatoid-like clinical presentation ob served both in humans and in transgenic mice for the Tax regulatory protein from HTLV-I (50) .
Regarding the failure to detect a precise cause of RA, recent studies with a new transgenic model have indicated that destructive arthritis can be present in the absence of an intraarticular antigen (51) . Whatever the 4) is provided by Th2 cells, whereas both Th2 cells and macrophages (Macr) contribute to IL-10 and transforming growth factor 0 (TGFb) levels. These regulatory cytokines will interfere with the Thl/Th2 balance, but a major effect will be related to inhibition of tumor necrosis factor (TNF)/IL-1 production. Moreover, direct effects on chondrocytes (Chondr) as well as osteoclasts (Osteoc)/osteoblasts (Osteob) in the bone should be taken into account. APC = antigen-presenting cell; IFN-g = interferon-7 ; Fibro = fibroblasts. conclusion, direct action on the cytokine balance repre sents a way to bypass the initiating event.
Thl/Th2 cytokine balance and the chronicity of RA. Increased migration of a large polyclonal population of T cell specificity results in the formation of the inflammatory lesion. Endothelial cell swelling, leading to the formation of high endothelial venules, is one of the earliest pathologic findings. These changes are asso ciated with increased expression of adhesion molecules, leading to increased cell migration. Migration of Thl cells, rather than Th2 cells, is facilitated through the use of the E and P selectins (52) . Thus, expression of such adhesion molecules is mandatory for an increase in the migration of T cells in a non-antigen-specific manner. These findings in various animal models suggest that it is of therapeutic interest to act on the migration of inflam matory cells. Indeed, targeting of intercellular adhesion molecule 1 has been applied in the treatment of RA (53) . To further refine such a concept, a more specific approach would be to block the migration of diseaseinducing Thl cells and favor that of the protective Th2 cells (54) .
These changes in migration pattern are associ ated with differences between systemic and synovial sites. During chronic inflammation, migration of proinflammatory cells is increased, whereas that of protective cells is defective, leading to their relative accumulation in the bloodstream (52) . In blood from RA patients, defects in IFNy production have been reported (55) . Results with very sensitive IL-4 assays indicated that activated RA whole blood cells produced more IL-4 than did controls, and with a higher IL-4:IFNy ratio. Such findings are consistent with the increased produc tion in blood as well as in activated peripheral blood mononuclear cell supernatants of soluble CD23, the production of which is enhanced by IL-4 (56) . results are in contrast to those found in the RA syno vium, where a Thl pattern is predominant.
Thl/Th2 cytokine balance as a therapeutic animal models
in Direct targeting of cytokines. Results in various models have indicated that control tory diseases can be achieved in the absence of a direct action on the antigen. The regulatory role of IL-4 and IL-10 has been convincingly demonstrated in most, but not all, animal models of arthritis (57) (Figure 4 ). IL-10 production is found in the synovial tissue of DBA/1 mice shortly after the onset of autoimmune collagen arthritis, and animals receiving neutralizing anti-IL-10 antibodies display an accelerated disease onset and more severe arthritis (58, 59) . Anti-IL-4 treatment around the time of the spontaneous onset of arthritis did not provoke enhanced severity (59) , underlining a more dominant role of IL-10 in endogenous control, which is consistent with low levels of IL-4 in the arthritic tissue. However, combined treatment with antibodies against both cyto kines resulted in the highest incidence and severity, indicating a significant contribution of IL-4 in disease control.
It is still unclear how much of the endogenous IL-10 is contributed to by Th2 lymphocytes. It seems likely that a large part of IL-10 in the arthritic synovial tissue is of macrophage origin. This may simultaneously explain the relative lack of IL-4 as compared with IL-10. Unlike IL-10, IL-4 is a selective product of T cells, with a minor contribution from local tissue mast cells. Con sistent with observations in arthritis, IL-10 exerts a similar controlling role in other diseases, such as auto immune encephalomyelitis, thyroiditis, and colitis (60) . Besides IL-10, TGF/3 also provides disease control, as shown by signs of spontaneous colitis both in IL-10-and TGF/3-deficient mice (61, 62) . Likewise, TGF/3 may be derived from T cells as well as from tissue macrophages.
Although rather high levels of IL-10 and TGF/3 can be found in arthritic tissue, further suppression of arthritis can still be achieved by exogenous application. Progression of established collagen arthritis could be ameliorated by daily treatment with IL-10 (63), but better suppression was found after combination treat ment with IL-4 and IL-10. The mechanism of this synergistic protection is linked to a more optimal sup pression of both TNFa and IL-1 production, and to a marked up-regulation of the IL-1 receptor antagonist (IL-lRa)/IL-l balance in synovium and cartilage (59) . Moreover, there is evidence that IL-4 has a direct protective effect against chondrocyte-driven cartilage degradation (64) .
Induction of endogenous protective cytokines. Although the therapeutic efficacy of daily IL-4/IL-10 treatment has now been proven in animal models of arthritis, it remains a challenge to avoid daily dosing and to find optimal ways to increase the endogenous produc tion of suppressive cytokines at the site or to suppress the continued generation and propagation of Thl cells. Strongly polarized T cell phenotypes are probably most relevant to chronic diseases that are characterized by continued antigen exposure, since it was found that reversibility of Thl and Th2 phenotypes was lost after prolonged in vitro antigen stimulation (65) . Despite major efforts in sophisticated animal models using T cell lines or clones, our understanding of regulation in conventionally immunized animals is still scant. More over, regulation seems rather different in early and late disease.
IL-12 is now recognized as a critical cytokine in the generation of Thl cells. It is produced in large quantities upon activation of macrophages with bacterial stimuli. IL-12 can replace bacteria in adjuvant prepara tions, and this cytokine may be the natural link between intercurrent infections and relapses of autoimmune dis eases. In murine collagen-induced arthritis, IL-12 mark edly enhanced disease expression and severity when given during immunization (66) or at the time of ex pected onset, whereas anti-IL-12 treatment prevented arthritis onset (67) . However, in established arthritis, regulation by IL-12 seems more complex. Exacerbations were noted after late anti-IL-12 treatment, apparently linked to IL-12-mediated induction of IL-10 (67). The latter phenomenon may represent a natural feedback mechanism that controls for largely skewed, and there fore pathogenic, Thl responses. The bimodal activity of IL-12 will seriously complicate IL-12-directed therapy in arthritis.
Induction of bystander suppression. Of interest, activated Th2/Th3 cells may protect individuals from Thl-dependent arthritis through antigen-driven genera tion of IL-4, IL-10, or TGF/3. The principle of so-called bystander suppression through this set of cytokines provides a means of bypassing the lack of information on particular autoantigens involved in the (68) ( Figure 5 ). Accepted ways to achieve Th2/Th3 responses are antigen dosing at mucosal surfaces, through the oral or nasal route, and stimulation with modified antigens (69, 70) . Oral dosing has a tendency to mainly generate Th3, TGF/3-dependent suppression. This was demon strated by a loss of protection after treatment with neutralizing anti-TGF/3 antibodies, whereas this path way was still functional in IL-4-deficient mice (71) . In contrast, studies with modified dence for the existence of an IL-4 and it seems likely that multiple mecnamsms may operational (72) . Of interest, treatment with nondeplet ing anti-CD4 antibodies during early antigen exposure caused a shift from Thl to IL-4-producing Th2 cells (73) , thus providing another means of manipulating T cell cytokine balance.
Although major research in this area has focused on understanding the immunoregulation mechanisms in autoimmune models such as encephalomyelitis and co litis (74) , results in arthritis models have shown suppres sion of disease upon oral dosing with type II collagen (75, 76) . Although the principle of using an autoantigen Cartilage "Antigens"
Proteoglycans, Collagen II,... Figure 5 . Bystander suppression to regulate arthritis. This scheme depicts propagation of chronic arthritis by arthritogenic epitopes released from the articular cartilage, which then stimulate Thl cells in the synovial tissue. In principle, any cartilage epitope released from the articular cartilage during normal tissue turnover, or enhanced during arthritic processes, might be considered a jointspecific bystander stimulus, provided that we are able to enrich sufficient Th2 or Th3 cells with the desired epitope specificity at the site. These cells will then release suppressive mediators (interleukin-4 [IL-4], transforming growth factor ¡3 [TGFb]) to control the arthritogenic Thl reaction. Likewise, endogenous proteins abundantly present under inflamed conditions in the synovial tissue, such as endogenous heat-shock proteins (hsp), may fulfill a similar role, if we are able to manipulate the T cell reactivity to these molecules in the desired direction (68) . Finally, exogenous antigens (Ag) can be artificially "planted" in the joint by local injection, in the context of proper Th2/ Th3 reactivity previously induced by preimmunization/tolerization against the selected antigen. The selectivity of such epitopes for Thl/Th2/Th3 cells will determine the net effect and safety.
from the articular cartilage of the joint to create local generation of protective bystander cytokines at the site seems an attractive approach, the major hurdle is the Oral or nasal dosing will generate Th2/Th3 T cells selectins (52) , such Th2 cells may not end up in large quantities at the desired spot.
Acting on the Thl/Th2 cytokine balance to control RA
Effect of exogenous cytokines. Preclinical studies have been performed with synovium pieces and cell suspensions obtained after enzymatic digestion. Addi tion of exogenous IL-4, IL-13, and to a lesser extent, IL-10 to synovium pieces strongly reduced the produc tion of proinflammatory cytokines, whereas the produc-but it will be limited by the number of affected joints. Preliminary phase I trials have started in RA, using the systemic administration of IL-10 and IL-4.
Administration of cytokine by gene therapy has proven to be successful in animal models of arthritis (83) , but the precise local control of such genes remains to be resolved. Another means could be the ex vivo stimulation of circulating lymphocytes with exogenous cytokines with reinjection of the cells. Such a procedure has already been used with IL-2 to obtain lymphokineactivated killer cells in the treatment of cancer. Ex vivo activation with Th2 cytokines can be a way to induce the differentiation of uncommitted or Thl cells into Th2 cells.
Induction of the endogenous production of pro tective cytokines. Induction of a remission or cure of RA has been observed in a number of clinical conditions in the absence of an obvious action at the level of the cause (9) . These conditions are important to consider, since it is tempting to attempt to reproduce such modulation for a longer period. The most obvious situation is the remission of RA that is observed during pregnancy and the flare that follows delivery. In this situation, T cell-mediated immunity-rejection of the fetus-must be down-regulated, whereas the fetus has to be pro tected with maternal IgG (84) . These 2 components suggest the contribution of factors such as TGF/3 and IL-10. Indeed, high levels of expression of IL-10 at the placental interface have been observed in the mouse (85) . More importantly, the improvement in RA appears to be directly related to the degree of maternal-fetal disparity, which leads to an increased need for fetal tolerance (86) . Similar observations have been made for the side of slow-acting (87), for early human immunodeficiency virus infection (88) , and for allogeneic bone marrow transplantation (89) (Figure 2) . These conditions appear to be associated with a Th2 cytokine profile (8, 90) (Figure 2) . Whatever the mechanism, such observations in dicate that even longstanding inflammatory disease can improve without antigen-specific intervention. The next logical step is to reproduce these situations in vitro and in vivo. Although the clinical data from the first small trials of type II collagen dosing in RA patients looked promising (91), more extended studies did not confirm efficacy (92) , and we are yet at the beginning of explor ing focused manipulation of local Thl/Th2/Th3 bal ances. Nevertheless, induction of bystander suppression by oral tolerance could represent a simple way to control inflammation.
It should be kept in mind that excessive Th2 switching may be harmful. Excesses of IL-4 and IL-13 could lead to allergy and asthma. An excess of IL-10 could favor B cell/plasma cell activation with increased autoantibody production. Such events may contribute to some extraarticular manifestations such as rheumatoid vasculitis or lymphomas that are seen during the course of RA.
Conclusion
The concept of cytokine balance in arthritis is appealing since it leads to treatment even if the cause of the "ase cannot be identified. This implies early treatment before destruction in patients at high risk. The genetic and hormonal backgrounds are obviously linked to RA severity. Recent findings suggest that the invasive pattern of RA synoviocytes is associated with, and may be the consequence of, irreversible somatic mutations (93) . If this is the case, then endogenous control of such proliferation may remain limited when the disease be comes chronic. Taken together, these factors strongly point to the need for better early diagnosis and prog nostic markers to ensure early treatment. In this situa tion, acting on the endogenous regulatory cytokine balance may represent a more natural way to prevent the consequences of chronic inflammation.
